These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17577620)

  • 1. Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer.
    Barone C; Basso M; Schinzari G; Pozzo C; Trigila N; D'Argento E; Quirino M; Astone A; Cassano A
    Gastric Cancer; 2007; 10(2):104-11. PubMed ID: 17577620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
    Turkeli M; Aldemir MN; Cayir K; Simsek M; Bilici M; Tekin SB; Yildirim N; Bilen N; Makas I
    Asian Pac J Cancer Prev; 2015; 16(3):985-9. PubMed ID: 25735393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer.
    Kim KH; Park YS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Park JO; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):347-53. PubMed ID: 19066894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer.
    Chen JS; Chen YY; Huang JS; Yeh KY; Chen PT; Shen WC; Hsu HC; Lin YC; Wang HM
    Gastric Cancer; 2012 Jan; 15(1):49-55. PubMed ID: 21655995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen.
    Murad AM; Skare NG; Vinholes J; Lago S; Pecego R;
    Gastric Cancer; 2006; 9(2):99-105. PubMed ID: 16767365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
    Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer.
    Kim JY; Ryoo HM; Bae SH; Kang BW; Chae YS; Yoon S; Baek JH; Kim MK; Lee KH; Lee SA; Song HS; Kim JG
    Anticancer Res; 2015 Jun; 35(6):3531-6. PubMed ID: 26026121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
    Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
    JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
    Pernot S; Mitry E; Samalin E; Dahan L; Dalban C; Ychou M; Seitz JF; Turki H; Mazard T; Zaanan A; Lepère C; Vaillant JN; Landi B; Rougier P; Taieb J
    Gastric Cancer; 2014 Apr; 17(2):341-7. PubMed ID: 23739764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
    El-Rayes BF; Zalupski M; Bekai-Saab T; Heilbrun LK; Hammad N; Patel B; Urba S; Shields AF; Vaishampayan U; Dawson S; Almhanna K; Smith D; Philip PA
    Ann Oncol; 2010 Oct; 21(10):1999-2004. PubMed ID: 20332133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
    Richards D; McCollum D; Wilfong L; Sborov M; Boehm KA; Zhan F; Asmar L
    Ann Oncol; 2008 Jan; 19(1):104-8. PubMed ID: 17897959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
    Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
    Yilmaz U; Oztop I; Alacacioglu A; Yaren A; Tarhan O; Somali I
    Chemotherapy; 2006; 52(5):264-70. PubMed ID: 16873996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
    Lim JY; Cho JY; Paik YH; Lee DK; Lee SI; Park HJ; Lee SJ; Lee KS; Yoon DS; Choi SH
    Oncology; 2007; 73(1-2):2-8. PubMed ID: 18332648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
    Dalla Chiesa M; Tomasello G; Buti S; Rovere RK; Brighenti M; Lazzarelli S; Donati G; Passalacqua R
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):41-8. PubMed ID: 20204366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen.
    Tomasello G; Chiesa MD; Buti S; Brighenti M; Negri F; Rovere RK; Martinotti M; Buononato M; Brunelli A; Lazzarelli S; Donati G; Passalacqua R
    Tumori; 2010; 96(1):48-53. PubMed ID: 20437857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.